+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07733180

Evaluating Tislelizumab with Chemotherapy in Japanese Adults with Advanced Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Using Alternate Dosing Schedules

Led by BeOne Medicines · Updated on 2026-10-26

30

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the pharmacokinetics, safety, and effectiveness of tislelizumab given every 2 or 4 weeks in combination with chemotherapy as a first treatment for Japanese adults with untreated, advanced, unresectable, or metastatic esophageal squamous cell carcinoma ESCC. This study aims to understand how well this combination works to shrink or eliminate tumors and to monitor side effects in this patient group. Participants will be assigned to one of two groups Group 1 will receive tislelizumab every 2 weeks plus FOLFOX chemotherapy every 2 weeks, and Group 2 will receive tislelizumab every 4 weeks plus FOLFOX chemotherapy every 2 weeks. Both treatments involve intravenous infusions of chemotherapy drugs oxaliplatin, leucovorin, and 5-fluorouracil 5-FU. Treatment continues until the disease worsens, side effects become unacceptable, or consent is withdrawn. Throughout the approximately one-year study, participants will visit the clinic regularly for treatments, health evaluations, blood tests, and tumor imaging. Researchers will measure tislelizumab levels in the blood, record adverse events, and assess tumor responses using independent review. The study will also look at progression-free survival after 6 months to better understand treatment effects and safety over time.

CONDITIONS

Brief Title

A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here